On the agenda:

• Measuring Systemic Scleroderma Treatment Efficacy
• State of the Art Therapy in IBD: Optimal Positioning in Clinical Practice
• Evolving Role of Fecal Transplants in IMID
• Developments in Diagnostic and Treatment Strategies for Eosinophilic Granulomatosis with Polyangiitis
• Surgical Updates in IBD
• Clinical Advances in Atopic Dermatitis: Strategies to Optimize Patient Outcomes and Satisfaction
• Cutaneous Manifestations of Gastrointestinal Disease and Approach to Management
• New Insights in Eosinophilic Esophagitis Pathogenesis and Treatment
• The Current State of Psoriasis Treatment With Targeted Therapy
• Human Gut Microbiota and Immune-Mediated Inflammatory Disease
• Checkpoint Inhibitor Therapy for Patients with Immune-Mediated Inflammatory Diseases
• Addressing Disease Progression in Psoriatic Arthritis
• Advances in Biologic Therapies for Vasculitis
• Choosing Initial Treatment in New-Onset IBD
• Pemphigus Vulgaris: Strategies for Disease Identification and Management
• Addressing Unmet Needs in Giant Cell Arteritis with Novel Targeted Therapies
• Evaluation and Treatment of Erythema Nodosum, a Common Panniculitis
• The Role for Immunosuppressives in IBD in the Biologic Era
• Overcoming Knowledge and Access Barriers for Use of Biosimilars in the Management of IMIDs
• Optimizing Treatment Regimens: Therapeutic Drug Monitoring vs Empiric Dosing
• Immuno-Autonomics in Autoimmune Diseases

and few more

Format: Lectures, Case Presentations “Approaches to Care”, Lunch Innovation Theaters, Co-Chairs Complex Clinical Case Review, Patient Demonstration (Clinical Assessment of PSO/PsA), Hot Topics in IMID.

17 AMA PRA Category 1 Credits™ – maximum

17 CNE contact hours